Combination photodynamic therapy + sphingolipid analog LCL85 leads to autophagy, defective apoptosis and long‐term sensitization | Zendy

Separovic Duska | Zendy; Joseph Nicholas | Zendy; Breen Paul | Zendy; Saad Ziad H. | Zendy; Bielawska Alicja | Zendy

Premium

Combination photodynamic therapy + sphingolipid analog LCL85 leads to autophagy, defective apoptosis and long‐term sensitization

Author(s) -

Separovic Duska,

Joseph Nicholas,

Breen Paul,

Saad Ziad H.,

Bielawska Alicja

Publication year - 2012

Publication title -

the faseb journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.709

H-Index - 277

eISSN - 1530-6860

pISSN - 0892-6638

DOI - 10.1096/fasebj.26.1_supplement.852.13

Subject(s) - autophagy , photodynamic therapy , sensitization , ceramide , apoptosis , sphingolipid , programmed cell death , cancer research , viability assay , clonogenic assay , chemistry , microbiology and biotechnology , medicine , biology , immunology , biochemistry , organic chemistry

Two anticancer agents, LCL85 and photodynamic therapy (PDT) were combined to test whether the combination PDT/LCL85 evokes changes in the sphingolipid (SL) profile and promotes cell death. Short‐term exposure to PDT/LCL85 led to enhanced levels of C18‐, C20‐, and C20:1‐ceramide, and C18‐DHceramide, enhanced autophagy and defective apoptosis, without affecting cell viability. In contrast, long‐term clonogenic survival was reduced not only after PDT or LCL85, but even more after PDT/LCL85, supporting translational potential of PDT/LCL85.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research